Radius Health (NASDAQ:RDUS) was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research note issued to investors on Thursday.

A number of other research firms have also recently commented on RDUS. Cantor Fitzgerald reiterated a “buy” rating and set a $58.00 target price on shares of Radius Health in a research note on Friday, November 3rd. Zacks Investment Research cut Radius Health from a “hold” rating to a “sell” rating in a research note on Wednesday, October 4th. Jefferies Group reiterated a “hold” rating and set a $38.00 target price (up from $34.00) on shares of Radius Health in a research note on Wednesday, August 9th. Citigroup initiated coverage on Radius Health in a research note on Wednesday. They set a “neutral” rating and a $30.00 target price on the stock. Finally, Goldman Sachs Group reiterated a “neutral” rating and set a $45.00 target price on shares of Radius Health in a research note on Friday, October 6th. Three research analysts have rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the stock. Radius Health has a consensus rating of “Hold” and a consensus target price of $48.00.

Radius Health (NASDAQ:RDUS) traded up $4.19 on Thursday, reaching $31.60. 3,177,683 shares of the company’s stock were exchanged, compared to its average volume of 968,720. The company has a current ratio of 12.87, a quick ratio of 12.79 and a debt-to-equity ratio of 0.53. Radius Health has a 1 year low of $24.66 and a 1 year high of $49.39.

Radius Health (NASDAQ:RDUS) last posted its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.28) by ($0.03). The business had revenue of $13.50 million for the quarter, compared to analysts’ expectations of $6.90 million. During the same quarter last year, the company earned ($1.07) earnings per share. analysts expect that Radius Health will post -5.57 EPS for the current fiscal year.

In other news, major shareholder Growth N. V. Biotech acquired 50,000 shares of the stock in a transaction that occurred on Tuesday, November 14th. The shares were acquired at an average cost of $26.25 per share, for a total transaction of $1,312,500.00. Following the purchase, the insider now owns 5,698,799 shares of the company’s stock, valued at approximately $149,593,473.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Brent Hatzis-Schoch acquired 1,778 shares of the stock in a transaction that occurred on Friday, November 10th. The stock was purchased at an average price of $28.09 per share, for a total transaction of $49,944.02. Following the completion of the purchase, the vice president now directly owns 2,278 shares in the company, valued at approximately $63,989.02. The disclosure for this purchase can be found here. Insiders have bought a total of 367,678 shares of company stock worth $11,746,498 over the last quarter. Company insiders own 15.00% of the company’s stock.

Institutional investors have recently made changes to their positions in the stock. State of Wisconsin Investment Board bought a new stake in Radius Health in the 2nd quarter valued at about $1,176,000. Candriam Luxembourg S.C.A. raised its stake in Radius Health by 23.5% in the 3rd quarter. Candriam Luxembourg S.C.A. now owns 142,000 shares of the biopharmaceutical company’s stock valued at $5,474,000 after acquiring an additional 27,000 shares during the period. Vanguard Group Inc. raised its stake in Radius Health by 4.5% in the 2nd quarter. Vanguard Group Inc. now owns 3,145,717 shares of the biopharmaceutical company’s stock valued at $142,281,000 after acquiring an additional 135,071 shares during the period. State Street Corp raised its stake in Radius Health by 12.9% in the 2nd quarter. State Street Corp now owns 1,867,531 shares of the biopharmaceutical company’s stock valued at $84,473,000 after acquiring an additional 213,399 shares during the period. Finally, BlackRock Inc. raised its stake in Radius Health by 10.0% in the 2nd quarter. BlackRock Inc. now owns 2,893,641 shares of the biopharmaceutical company’s stock valued at $130,881,000 after acquiring an additional 262,896 shares during the period.

ILLEGAL ACTIVITY WARNING: “BidaskClub Downgrades Radius Health (RDUS) to Strong Sell” was first posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/09/bidaskclub-downgrades-radius-health-rdus-to-strong-sell.html.

About Radius Health

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Analyst Recommendations for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.